Neurobiology of Opioid Dependence: 1 - 1

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000192

Purpose

The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Lamotrigine	Phase II

Study Type:	Interventional
Study Design:	Treatment, Double-Blind, Placebo Control
Official Title:	Neurobiology of Opioid Dependence: 1

Resource links provided by NLM:

Drug Information available for: Lamotrigine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Behavioral, subjective, measures of naloxone-precipitated opiate withdrawal
Phsyiological, neuroendocrine measures of naloxone-precipitated opiate withdrawal

Estimated Enrollment:	0
Study Start Date:	January 1995

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000192

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators

Principal Investigator:

Marc I Rosen, M.D.

VA Connecticut Healthcare System

More Information

Publications:

Rosen, MI et al; Drug and Alcohol Dependence, 1998: 52:p173-176. CPDD, 1996 Meeting.

Study ID Numbers:	NIDA-00191-1, K20-00191-1
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000192 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Molecular Mechanisms of Pharmacological Action
Disorders of Environmental Origin
Calcium Channel Blockers
Cardiovascular Agents
Opioid-Related Disorders
Pharmacologic Actions
Membrane Transport Modulators

Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Lamotrigine
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on November 09, 2009